Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report

Lee, Yeong Yeh; Tee, Vincent

doi:10.7573/dic.2023-2-10

Cited by 3 publications

(4 citation statements)

References 10 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 Furthermore, the prolonged and excessive usage of herbal supplements, traditional medicines and dietary supplements has emerged as a significant contributor to HILI. 18,24 Notably, in the collection of clinical cases across the globe presented in this series, [5][6][7][8][9][10] at least one risk factor was found to be present in all the described CLD cases (except for DILI). This finding is in alignment with the available literature around NAFLD/MAFLD, where most patients have one or more risk factors, including overweight/obesity, T2D, dyslipidaemia or cardiovascular complications like hypertension.…”

Section: Risk Factorsmentioning

confidence: 67%

“…In this case, liver biopsy helped the clinician to identify the severity and progression of MAFLD to metabolic-associated steatohepatitis (MASH) with steatosis and advanced fibrosis (F3–S3). 5 In addition, in the case presented by Lee and Tee, 8 an ultrasound-guided liver biopsy supported the diagnosis of grade II NASH.…”

Section: Reviewmentioning

confidence: 86%

“…This review is an opening paper to the clinical case collection entitled 'Current clinical use of silymarin in the treatment of toxic liver diseases: a case series', focused on the management and treatment of major liver diseases with silymarin. [5][6][7][8][9][10]…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Chronic liver disease and management with silymarin: an introductory review of a clinical case collection

Angelico

2024

DIC

View full text Add to dashboard Cite

Chronic liver disease (CLD) is a significant global health concern and generally leads to fibrosis, cirrhosis and hepatocellular carcinoma. Various factors, such as metabolic abnormalities, viral infections, alcoholism, genetics and autoimmune responses, contribute to liver damage. CLD is characterized by different phenotypes, including non-alcoholic fatty liver disease, metabolic-associated fatty liver disease, drug-induced liver injury and alcoholic liver disease. These conditions have seen an increase in comorbidities and hospitalizations over the past decade, imposing a substantial burden on patients and healthcare systems. Understanding the underlying mechanisms of liver injury is crucial for effective management and reducing the clinical and economic burden of CLD. Although several attempts have been evaluated to find a drug therapy option for the management of non-alcoholic fatty liver disease and metabolic-associated fatty liver disease, there is no effective drug approved to date. However, different studies have demonstrated that silymarin, the milk thistle extract, could exert hepatoprotective, antioxidant, anti-inflammatory and antifibrotic properties and should therefore be considered an efficacious, tolerable and promising herbal product for the management of liver activity in CLDs. This review discusses the clinical features, diagnosis and available treatments for major liver diseases, acting as an introduction to a clinical case collection based on the management and treatment of major liver diseases with silymarin. This article is part of the Current clinical use of silymarin in the treatment of toxic liver diseases: a case series Special Issue: https://www.drugsincontext.com/special_issues/current-clinical-use-of-silymarin-in-the-treatment-of-toxic-liver-diseases-a-case-series

show abstract

Section: Risk Factorsmentioning

confidence: 67%

Section: Reviewmentioning

confidence: 86%

See 1 more Smart Citation

Chronic liver disease and management with silymarin: an introductory review of a clinical case collection

Angelico

2024

DIC

View full text Add to dashboard Cite

show abstract

“…Various studies have been conducted or are ongoing to further confirm the evidence on silymarin and improve its clinical use. [54][55][56][57][58][59]…”

Section: Role Of Oxidative Stress Management In Mafld Treatmentmentioning

confidence: 99%

Review and expert opinion on MAFLD, oxidative stress and multifunctional management

Angelico,

Alcantara-Payawal,

Rani

et al. 2024

DIC

View full text Add to dashboard Cite

Metabolic-associated fatty-liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is the most widespread and emerging chronic liver disease worldwide, with increasing prevalence rates also in the Asia-Pacific region. The disease has a high socio-economic burden as it negatively impacts the finances and quality of life of individuals affected and has a major burden on healthcare systems. The most important pathological event in MAFLD aetiopathogenesis is oxidative stress, which leads to functional and structural abnormalities in the liver as well as being involved in the development of other concomitant cardiometabolic diseases. MAFLD is a rather complex multisystemic clinical condition involving liver damage and a wide spectrum of extrahepatic manifestations such as obesity, type 2 diabetes, metabolic syndrome and cardiovascular diseases. This complexity requires the cooperation of multiple experts to identify MAFLD at an early stage, treat associated comorbidities, and promptly refer the patient to the hepatologist when needed. This review summarizes the current knowledge about MAFLD and reports the opinion of a group of experts on the increasing prevalence and burden of the disease in the southeast Asia region, the current journey of patients with MAFLD in developing countries, the role of oxidative stress and antioxidant treatment, and the importance of a multidisciplinary approach for early diagnosis and disease management. This article is part of the Current clinical use of silymarin in the treatment of toxic liver diseases: a case series Special Issue: https://www.drugsincontext.com/special_issues/current-clinical-use-of-silymarin-in-the-treatment-of-toxic-liver-diseases-a-case-series

show abstract

Multiple drugs

2023

Reactions Weekly

View full text Add to dashboard Cite

Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report

Cited by 3 publications

References 10 publications

Chronic liver disease and management with silymarin: an introductory review of a clinical case collection

Chronic liver disease and management with silymarin: an introductory review of a clinical case collection

Review and expert opinion on MAFLD, oxidative stress and multifunctional management

Multiple drugs

Contact Info

Product

Resources

About